Europe’s Pharma Pain such as Trump Tarif’s Threat Machines

Insulin, heart treatment and antibiotics flowed frequently on many borders for decades, Be free of tariffs in an offer to take medicine. But it can change soon.

Over the months, President Trump promises to apply high tariffs to pharmaceuticals as the Presidential Trump has resorted the global trading system and plan to bring the main production industry to the United States. This month, said pharmaceutical tariffs could come “Too far away.”

If they do, the action was serious – and we will be savagely for drugs made in the European Union.

Pharmaceutical products and chemicals are blocked Export number 1 To America. Among them are blockbuster ozempti, cancer treatment, cardiovascular medicines and flu vacvics. Most of them are ad-branded ad-brand drugs that make a great profit in the American market in many high prices and many consumers.

“These are critical things that keep people alive,” he said. “It was a lot to put them in the middle of the trade war.”

European companies can react to Mr. Trump tariffs in a number of ways. Some pharmaceutical companies trying to avoid tariffs, Mr. Trump announced that they plan to increase production in the United States. Others can then decide to move the production there.

Other companies seem to be placed, but can cover the tariffs to cover the tariffs and increase the costs for patients. And higher prices can affect not only American consumers, but also to patients in Europe. Some companies have started move This must create more favorable conditions for their jobs by demolishing some rules that lower the price of drugs.

OR Some Middle Ground Could Play Out: Companies Might Shift Their Financial Profits To The United States for Accounting Purposes To Avoid Impor Charges, Even as They Leave Huving and Challenges of Having and Challenges of Having and Challenges Of Having and Challenges of Having and Challenges Of Having and Challenges of Having and Challenges Of Having and Challenges Of Having and Challenges of Having and Challenges Of Having and Challenges Of Having and Challenges Of Having and Challenges Of Having and Challenges Of Having and Challenges Of Having and Challenges Of Having and Challenges of Having to Set Up New Supply Chains.

Ms. Aufreth group has already warned European officials that in return, they should not retreat in an important industry by tariffing American medicines.

However, the pharmaceutical sector is complicated. With insurance companies and government agencies, contracts can complicate rapid regulation for branded drugs, and government rules can act as a problem and long-term liability. The top is that no one can predict the result with confidence.

“We have not tariffed for a long time,” he said, an economist, an economist and tax rules presented by foreign production in the foreign production economy.

Mr. Trump, as the Hiatus suspended “mutual” tariffs in favor of each other in the period, the tariffs in some industries were left in place and computer chips and pharmaceutical products will be next. Recently the United States Started research The first step to hit both sectors and tariffs.

Many industrial specialists expect 25 percent of new tariffs, steel, aluminum and cars in accordance with those in cars.

Possible tariffs for countries in the center of the European drug industry are particularly concerned. This is true of Ireland, especially for Ireland, especially for 80 percent of all exports to the United States.

Many drugs first moved to Ireland because they presented very low corporate tax rates. However, it also offers its pharmaceutical industry and access to a highly qualified business.

In recent years, the sector has grown rapidly. Much more 90 Pharmaceutical Company It is now located there, so Irish Foreign Investment AgencyAnd many of the largest America have operations in the nation. Last year, Ireland exported the Pharma Industry 58 billion eurosor about $ 66 billion in pharmaceutical and chemical products leading to the United States.

“Irish are smart, yes, smart people,” Mr. Trump, in March, said that Ireland Micheweál Martin visited the White House. “You took our pharmaceutical companies and other companies,” he said. “This beautiful island of five million people are in his grasps in the entire US pharmaceutical industry.”

Now tariffs can go away from the benefits of production – this is the purpose of Mr. Trump.

“We do not do our medicines in the United States,” Mr. Trump said, “Drug companies in Ireland,” the Oval office said.

Firms are already amended. The companies rushed to fall from Ireland from Ireland to the Frenchman and the US market, The statistics offers.

Northern Ireland, the only country of Iceland. Dadir in Germany, Belgium, Denmark and Slovenia Great exporter.

“This is a great issue for Europe,” he said.

European leaders went to both American officials and the industry. In addition to the last visit of the Irish Prime Minister, Ireland went to Washington to meet with the Irish Foreign Minister Trading Secretary.

President of the European Commission, the European Commission of the European Commission, Ursula Von Der Leien, met with European Federations and Associations in Brussels, the Lobby group representing the largest pharmacies in Europe.

The industry uses the moment of pushing items like less red ribbon.

The European Drug Lobby Group told Mrs. Von Der Leyen that companies are more attractive to the United States, especially faster confirmation and easier access to the US TRUC’s tariffs.

At least 18 members of the group, which included Bayer, Pfizer and Merck, planned about 165 billion euros to the European Union for the next five years. The federation said half a half as half of the half could pass to the United States. Also, this forecast is not alone.

“Pharma needs more attractive conditions to produce Europe,” he said, Dorothee Brakmann, the largest association of Germany’s largest medicinal companies in Pharma Deutschland.

Such warnings have teeth. Some companies have begun to plan more in the United States; Roche firm declared last week $ 50 billion in American investment planmost recent a string Such ads.

Last week, in a statement, Novartis and Sanofi’s chief leaders said that less arrangements to tune the bleeding were enough. “European price control and stiffness measures reduce the attractiveness of its markets,” and the block claimed that the block should lead to a higher price.

Industrial executors also warned that tariffs for the sector tariffs may violate the supply lines, violating the patient’s entry and disrupt the investigation and development.

“There is a reason,” the tariffs in the drugs are zero, Joaquin Duato, Drugmaker Johnson & Johnson’s CEO, said Last Gains Call. “These tariffs can lead to a lack of arising in the supply chain.”

Ms. Stressed similar concerns from the land, warning Tariffs on the pharmaceutical sector “The effects of global supply chains and drugs for European and US patients”.

Pharmaceutical tariffs also keep another threat to the European Union.

The block is more than brand products, but often prepared in Asia, but very little is trying to produce the ability to produce common medications.

However, US tariffs can suddenly send a smaller pill to the general drug manufacturers in China and India, looking for customers outside of America.

This can be further difficult for the European Union to establish a local production base for the general production base, and even leads to the United States.

“We think this will cause this to invest in the United States,” he said. “The European Commission needs to be in the ball.”